Search Browse Earnings

Karyopharm Therapeutics Inc. — SlamSEC

Karyopharm Therapeutics Inc.

Nasdaq:KPTI

Pharmaceutical Preparations·NEWTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$146.0M

-7.0% YoY

FY 2025

Adj. EBITDA

-$128.8M

-88.2% margin

FY 2025

Net Income

-$143.1M

-98.0% margin

FY 2025

EPS (Diluted)

-$18.79

FY 2025

Stock Price

$8.62

-2.4%

2026-03-09

52W Range

$3.51 – $10.99

P/E Ratio

-0.5x

Market Cap

$158.1M

Cash

$52.2M

FY 2025

Total Debt

$169.3M

FY 2021

Net Debt

$117.1M

FY 2021

Enterprise Value

$275.2M

Debt / EBITDA

-0.9x

FY 2025

EV / EBITDA

-2.1x

Employees

—